The new triple inhalers containing an inhaled corticosteroid, long-acting muscarinic antagonist and long-acting beta-2 agonist have recently been licensed for the management of people with COPD. Using one inhaler containing three medicines may help to support adherence, although there is no evidence to confirm this, and they will reduce NHS costs. However, this only applies if they are prescribed in those patients that clinically require all three classes of medicine. We know that too many of our COPD patients are unnecessarily prescribed inhaled corticosteroids, increasing the cost and potential adverse side-effects for the patient. We must phenotype our COPD appropriately as per national guidelines so that prescribing of the triple therapy inhalers are prescribed safely and appropriately.